Topic: irritable bowel syndrome (IBS)
Arena Pharma says cannabinoid receptor-targeting olorinab could help treat the pain associated with Crohn’s disease.
Urovant filed to raise $150 million in its IPO, which will push the company's lead asset through the clinic in a pair of indications.
Ardelyx has announced chief scientific officer Jeremy Caldwell, Ph.D., is heading for the exit, with no replacement yet lined up.
Ardelyx now has a second positive phase 3 trial for its constipation-predominant irritable bowel syndrome drug tenapanor.
Ardelyx says it has hit its primary endpoint and most of its secondary endpoints in a late-stage test of its IBS (with constipation) candidate tenapanor, but investors were spooked as its shares spiraled downward premarket.
In this week's EuroBiotech Report, Astellas moves to buy Ogeda, Verona files for IPO, Merck KGaA spinoff pens IBD pact and more.
Ironwood is already chalking up success with its first colonic delivery drug Linzess, but analysts reckon another payoff could come from two follow-up drugs.